unknown
Stage
1
Investors
About
Aviceda develops novel glyco-immune checkpoint therapeutics focusing on treatments for immune-mediated diseases, with a lead program targeting macular degeneration.
Explore Aviceda's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.